Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lackluster Survival Data Likely To Marginalize MacroGenics’ Margenza

Executive Summary

While the general lack of an overall survival benefit for MacroGenics’ drug in later-line breast cancer was not surprising, OS data were seen as important for commercial uptake of the drug.

You may also be interested in...



Leap Therapeutics And MacroGenics Among Early Winners And Losers At ESMO

Two companies looking to challenge Merck’s Keytruda with new combinations have had contrasting reactions from investors

Enhertu Could Get Big Boost From Second-Line Breast Cancer Indication

An analyst forecast that about 40% of the drug’s sales could come from second-line disease, while lack of grade 4-5 interstitial lung disease events was seen as a plus.

MacroGenics Gets Nod For Margenza In HER2-Positive Breast Cancer

The drug may see a muted launch given the competitive landscape and a broad label despite its efficacy advantage in F-allele patients.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145036

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel